ÂÜÀòÂÒÂ×

David Grainger is a prominent figure in the biotech and pharmaceutical industries, serving as Chairman and Founder of RxCelerate Limited since April 2014, where David offers outsourced drug development services. As a Partner at Medicxi since February 2016, David plays a crucial role in investing in early-stage life sciences companies. Previously, David held the position of Chief Innovation Officer at Centessa Pharmaceuticals from October 2021 to January 2024, overseeing non-clinical portfolios, and has been involved in multiple leadership roles, including Executive Chairman at Total Scientific Ltd and Partner at Index Ventures. David founded several companies, including TCP Innovations Ltd and Funxional Therapeutics Ltd, and has an extensive academic background as a Principal Investigator at Cambridge University, focusing on chronic inflammation research. David holds a First Class Honours M.A. and Ph.D. in Natural Sciences from the University of Cambridge.